Clinical Trials

Blog Post

MDA Ambassador Guest Blog: Finding Hope and Optimism in New Treatments

By Chase Rankin | June 4, 2024
Woman in electric wheelchair waits for consultation with doctor in clinic waiting area. Nurse invites patient with disability on procedures. Medical staff and people in modern medical facility lobby.
Blog Post

Treatment Options for Autoimmune Neuromuscular Diseases

By Patrick Sullivan | May 17, 2024
Illustration of digital health technologies
Featured Article

Can Wearables and Smartphones Make Clinical Trials Better?

By Andrew Zaleski | May 9, 2024
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Blog Post

Simply Stated: Updates in SELENON-Related Myopathy

By Sujatha Gurunathan | May 7, 2024
Blog Post

Clinical Study Alert: Phase 2 Study of Vamorolone in Adults with BMD

By Sujatha Gurunathan | April 2, 2024
Blog Post

Clinical Study Alert: Phase 2 Study of Brogidirsen in Boys with DMD

By Sujatha Gurunathan | March 29, 2024
Blog Post

Clinical Study Alert: A Phase 1/2 Study of Safety and Efficacy of LX2006 Gene Therapy in Adults with Cardiomyopathy Associated with Friedreich Ataxia

By Sujatha Gurunathan | March 25, 2024
Blog Post

FDA’s Approval of Duvyzat (givinostat) Offers New Hope to People Living with Duchenne Muscular Dystrophy

By MDA Staff | March 21, 2024
The key pathologic change of the muscular dystrophy is the myonecrosis. At an early phase, necrotic fibers appear swollen, homogeneous and deeply eosinophilic. This disease is caused by mutations of dystrophin, the largest known human gene, located on chromosome Xq21.
Blog Post

Simply Stated: Updates in LAMA2 Muscular Dystrophy

By Sujatha Gurunathan | February 20, 2024
Illustration of a black metal pipeline on a yellow background
Featured Article

What Is the Drug Development Pipeline?

By Amy Bernstein | February 12, 2024